Which has better valuation & earnings, CADL or NNNN?

Anbio Biotechnology has higher revenue and earnings than Candel Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Candel Therapeutics N/A N/A -$38.18M -$0.98 N/A Anbio Biotechnology $8.65M 241.70 $6.40M N/A N/A

Is CADL or NNNN more profitable?

Anbio Biotechnology's return on equity of 0.00% beat Candel Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Candel Therapeutics N/A -60.42% -41.33% Anbio Biotechnology N/A N/A N/A

Which has higher earnings and valuation, CADL or BHVN?

Candel Therapeutics is trading at a lower price-to-earnings ratio than Biohaven, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Candel Therapeutics N/A N/A -$38.18M -$0.98 N/A Biohaven N/A N/A -$738.82M -$5.67 N/A

Is CADL or BHVN more profitable?

Candel Therapeutics' return on equity of -60.42% beat Biohaven's return on equity. Company Net Margins Return on Equity Return on Assets Candel Therapeutics N/A -60.42% -41.33% Biohaven N/A -866.46% -137.99%

Does the media favor CADL or BHVN?

In the previous week, Candel Therapeutics had 2 more articles in the media than Biohaven. MarketBeat recorded 6 mentions for Candel Therapeutics and 4 mentions for Biohaven. Biohaven's average media sentiment score of 0.58 beat Candel Therapeutics' score of 0.31 indicating that Biohaven is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Candel Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Biohaven 1 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable valuation and earnings, CADL or KOD?

Candel Therapeutics is trading at a lower price-to-earnings ratio than Kodiak Sciences, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Candel Therapeutics N/A N/A -$38.18M -$0.98 N/A Kodiak Sciences N/A N/A -$229.97M -$4.17 N/A

Is CADL or KOD more profitable?

Candel Therapeutics' return on equity of -60.42% beat Kodiak Sciences' return on equity. Company Net Margins Return on Equity Return on Assets Candel Therapeutics N/A -60.42% -41.33% Kodiak Sciences N/A -253.85% -81.48%

Does the media favor CADL or KOD?

In the previous week, Candel Therapeutics had 4 more articles in the media than Kodiak Sciences. MarketBeat recorded 6 mentions for Candel Therapeutics and 2 mentions for Kodiak Sciences. Kodiak Sciences' average media sentiment score of 1.38 beat Candel Therapeutics' score of 0.31 indicating that Kodiak Sciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Candel Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Kodiak Sciences 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better earnings & valuation, PHVS or CADL?

Pharvaris is trading at a lower price-to-earnings ratio than Candel Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Pharvaris N/A N/A -$198.79M -$3.18 N/A Candel Therapeutics N/A N/A -$38.18M -$0.98 N/A

Is PHVS or CADL more profitable?

Candel Therapeutics' return on equity of -60.42% beat Pharvaris' return on equity. Company Net Margins Return on Equity Return on Assets Pharvaris N/A -67.56% -61.13% Candel Therapeutics N/A -60.42% -41.33%

Does the media refer more to PHVS or CADL?

In the previous week, Candel Therapeutics had 1 more articles in the media than Pharvaris. MarketBeat recorded 6 mentions for Candel Therapeutics and 5 mentions for Pharvaris. Pharvaris' average media sentiment score of 0.46 beat Candel Therapeutics' score of 0.31 indicating that Pharvaris is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Pharvaris 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Candel Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Candel Therapeutics (CADL) Competitors

$9.79 0.00 (0.00%)

Closing price 06/26/2026 04:00 PM Eastern

Extended Trading

$9.76 -0.03 (-0.31%)

As of 04:17 AM Eastern

Compare

CADL vs. NNNN, BHVN, KOD, NTLA, and PHVS

Should you buy Candel Therapeutics stock or one of its competitors? MarketBeat compares Candel Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Candel Therapeutics include Anbio Biotechnology (NNNN), Biohaven (BHVN), Kodiak Sciences (KOD), Intellia Therapeutics (NTLA), and Pharvaris (PHVS). These companies are all part of the "pharmaceutical products" industry.

How does Candel Therapeutics compare to Anbio Biotechnology?

Candel Therapeutics (NASDAQ:CADL) and Anbio Biotechnology (NASDAQ:NNNN) are both pharmaceutical products companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, dividends, risk, valuation, analyst recommendations, profitability, media sentiment and earnings.

Anbio Biotechnology's return on equity of 0.00% beat Candel Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Candel Therapeutics	N/A	-60.42%	-41.33%
Anbio Biotechnology	N/A	N/A	N/A

In the previous week, Candel Therapeutics had 5 more articles in the media than Anbio Biotechnology. MarketBeat recorded 6 mentions for Candel Therapeutics and 1 mentions for Anbio Biotechnology. Anbio Biotechnology's average media sentiment score of 1.87 beat Candel Therapeutics' score of 0.31 indicating that Anbio Biotechnology is being referred to more favorably in the news media.

Company	Overall Sentiment
Candel Therapeutics	Neutral
Anbio Biotechnology	Very Positive

Candel Therapeutics currently has a consensus price target of $18.00, indicating a potential upside of 83.86%. Given Candel Therapeutics' stronger consensus rating and higher possible upside, equities research analysts clearly believe Candel Therapeutics is more favorable than Anbio Biotechnology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Candel Therapeutics	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.56
Anbio Biotechnology	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

Anbio Biotechnology has higher revenue and earnings than Candel Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Candel Therapeutics	N/A	N/A	-$38.18M	-$0.98	N/A
Anbio Biotechnology	$8.65M	241.70	$6.40M	N/A	N/A

Candel Therapeutics has a beta of -0.49, indicating that its share price is 149% less volatile than the broader market. Comparatively, Anbio Biotechnology has a beta of 4.4, indicating that its share price is 340% more volatile than the broader market.

13.9% of Candel Therapeutics shares are owned by institutional investors. 14.3% of Candel Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

Candel Therapeutics and Anbio Biotechnology tied by winning 6 of the 12 factors compared between the two stocks.

How does Candel Therapeutics compare to Biohaven?

Candel Therapeutics (NASDAQ:CADL) and Biohaven (NYSE:BHVN) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, profitability, media sentiment, valuation, institutional ownership, analyst recommendations, risk and dividends.

Candel Therapeutics is trading at a lower price-to-earnings ratio than Biohaven, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Candel Therapeutics	N/A	N/A	-$38.18M	-$0.98	N/A
Biohaven	N/A	N/A	-$738.82M	-$5.67	N/A

13.9% of Candel Therapeutics shares are owned by institutional investors. Comparatively, 88.8% of Biohaven shares are owned by institutional investors. 14.3% of Candel Therapeutics shares are owned by company insiders. Comparatively, 13.8% of Biohaven shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Candel Therapeutics has a beta of -0.49, suggesting that its stock price is 149% less volatile than the broader market. Comparatively, Biohaven has a beta of 1.35, suggesting that its stock price is 35% more volatile than the broader market.

Candel Therapeutics' return on equity of -60.42% beat Biohaven's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Candel Therapeutics	N/A	-60.42%	-41.33%
Biohaven	N/A	-866.46%	-137.99%

Candel Therapeutics currently has a consensus price target of $18.00, suggesting a potential upside of 83.86%. Biohaven has a consensus price target of $22.27, suggesting a potential upside of 41.01%. Given Candel Therapeutics' higher possible upside, research analysts clearly believe Candel Therapeutics is more favorable than Biohaven.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Candel Therapeutics	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.56
Biohaven	1 Sell rating(s)	5 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	2.72

In the previous week, Candel Therapeutics had 2 more articles in the media than Biohaven. MarketBeat recorded 6 mentions for Candel Therapeutics and 4 mentions for Biohaven. Biohaven's average media sentiment score of 0.58 beat Candel Therapeutics' score of 0.31 indicating that Biohaven is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Candel Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Biohaven	1 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Candel Therapeutics and Biohaven tied by winning 7 of the 14 factors compared between the two stocks.

How does Candel Therapeutics compare to Kodiak Sciences?

Candel Therapeutics (NASDAQ:CADL) and Kodiak Sciences (NASDAQ:KOD) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, profitability, dividends, institutional ownership, valuation, analyst recommendations, risk and media sentiment.

13.9% of Candel Therapeutics shares are owned by institutional investors. Comparatively, 89.1% of Kodiak Sciences shares are owned by institutional investors. 14.3% of Candel Therapeutics shares are owned by insiders. Comparatively, 45.9% of Kodiak Sciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Candel Therapeutics presently has a consensus target price of $18.00, suggesting a potential upside of 83.86%. Kodiak Sciences has a consensus target price of $42.14, suggesting a potential upside of 17.26%. Given Candel Therapeutics' higher possible upside, research analysts plainly believe Candel Therapeutics is more favorable than Kodiak Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Candel Therapeutics	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.56
Kodiak Sciences	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

Candel Therapeutics is trading at a lower price-to-earnings ratio than Kodiak Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Candel Therapeutics	N/A	N/A	-$38.18M	-$0.98	N/A
Kodiak Sciences	N/A	N/A	-$229.97M	-$4.17	N/A

Candel Therapeutics has a beta of -0.49, suggesting that its share price is 149% less volatile than the broader market. Comparatively, Kodiak Sciences has a beta of 2.21, suggesting that its share price is 121% more volatile than the broader market.

Candel Therapeutics' return on equity of -60.42% beat Kodiak Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Candel Therapeutics	N/A	-60.42%	-41.33%
Kodiak Sciences	N/A	-253.85%	-81.48%

In the previous week, Candel Therapeutics had 4 more articles in the media than Kodiak Sciences. MarketBeat recorded 6 mentions for Candel Therapeutics and 2 mentions for Kodiak Sciences. Kodiak Sciences' average media sentiment score of 1.38 beat Candel Therapeutics' score of 0.31 indicating that Kodiak Sciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Candel Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Kodiak Sciences	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Candel Therapeutics and Kodiak Sciences tied by winning 6 of the 12 factors compared between the two stocks.

How does Candel Therapeutics compare to Intellia Therapeutics?

Intellia Therapeutics (NASDAQ:NTLA) and Candel Therapeutics (NASDAQ:CADL) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, media sentiment, profitability, analyst recommendations, institutional ownership, earnings, valuation and dividends.

Intellia Therapeutics has a beta of 1.92, indicating that its stock price is 92% more volatile than the broader market. Comparatively, Candel Therapeutics has a beta of -0.49, indicating that its stock price is 149% less volatile than the broader market.

88.8% of Intellia Therapeutics shares are owned by institutional investors. Comparatively, 13.9% of Candel Therapeutics shares are owned by institutional investors. 3.5% of Intellia Therapeutics shares are owned by company insiders. Comparatively, 14.3% of Candel Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Intellia Therapeutics currently has a consensus target price of $20.46, suggesting a potential upside of 22.64%. Candel Therapeutics has a consensus target price of $18.00, suggesting a potential upside of 83.86%. Given Candel Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Candel Therapeutics is more favorable than Intellia Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Intellia Therapeutics	3 Sell rating(s)	10 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.35
Candel Therapeutics	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.56

Candel Therapeutics has a net margin of 0.00% compared to Intellia Therapeutics' net margin of -597.04%. Intellia Therapeutics' return on equity of -57.47% beat Candel Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Intellia Therapeutics	-597.04%	-57.47%	-46.24%
Candel Therapeutics	N/A	-60.42%	-41.33%

In the previous week, Candel Therapeutics had 5 more articles in the media than Intellia Therapeutics. MarketBeat recorded 6 mentions for Candel Therapeutics and 1 mentions for Intellia Therapeutics. Intellia Therapeutics' average media sentiment score of 1.89 beat Candel Therapeutics' score of 0.31 indicating that Intellia Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Intellia Therapeutics	Very Positive
Candel Therapeutics	Neutral

Candel Therapeutics has lower revenue, but higher earnings than Intellia Therapeutics. Candel Therapeutics is trading at a lower price-to-earnings ratio than Intellia Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Intellia Therapeutics	$67.67M	34.44	-$412.69M	-$3.54	N/A
Candel Therapeutics	N/A	N/A	-$38.18M	-$0.98	N/A

Summary

Intellia Therapeutics and Candel Therapeutics tied by winning 8 of the 16 factors compared between the two stocks.

How does Candel Therapeutics compare to Pharvaris?

Pharvaris (NASDAQ:PHVS) and Candel Therapeutics (NASDAQ:CADL) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, profitability, dividends, analyst recommendations, media sentiment, institutional ownership, earnings and risk.

Pharvaris has a beta of -2.35, indicating that its share price is 335% less volatile than the broader market. Comparatively, Candel Therapeutics has a beta of -0.49, indicating that its share price is 149% less volatile than the broader market.

In the previous week, Candel Therapeutics had 1 more articles in the media than Pharvaris. MarketBeat recorded 6 mentions for Candel Therapeutics and 5 mentions for Pharvaris. Pharvaris' average media sentiment score of 0.46 beat Candel Therapeutics' score of 0.31 indicating that Pharvaris is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Pharvaris	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Candel Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Candel Therapeutics' return on equity of -60.42% beat Pharvaris' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pharvaris	N/A	-67.56%	-61.13%
Candel Therapeutics	N/A	-60.42%	-41.33%

Pharvaris is trading at a lower price-to-earnings ratio than Candel Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pharvaris	N/A	N/A	-$198.79M	-$3.18	N/A
Candel Therapeutics	N/A	N/A	-$38.18M	-$0.98	N/A

Pharvaris presently has a consensus price target of $49.64, suggesting a potential upside of 45.95%. Candel Therapeutics has a consensus price target of $18.00, suggesting a potential upside of 83.86%. Given Candel Therapeutics' higher possible upside, analysts plainly believe Candel Therapeutics is more favorable than Pharvaris.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pharvaris	1 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.69
Candel Therapeutics	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.56

13.9% of Candel Therapeutics shares are owned by institutional investors. 14.3% of Candel Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

Candel Therapeutics beats Pharvaris on 10 of the 13 factors compared between the two stocks.

Get Candel Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CADL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CADL vs. The Competition

Export

Metric	Candel Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$717.31M	$3.62B	$6.83B	$12.17B
Dividend Yield	N/A	2.21%	2.66%	6.11%
P/E Ratio	-9.99	21.75	25.90	24.17
Price / Sales	N/A	334.26	555.66	102.83
Price / Cash	N/A	62.10	29.09	36.93
Price / Book	10.31	8.31	10.78	6.38
Net Income	-$38.18M	$23.92M	$3.58B	$337.00M
7 Day Performance	6.99%	1.93%	1.97%	-0.20%
1 Month Performance	17.95%	-0.41%	-0.24%	-1.40%
1 Year Performance	99.80%	65.22%	34.39%	27.76%

Candel Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CADL Candel Therapeutics	2.7762 of 5 stars	$9.79 flat	$18.00 +83.9%	+99.8%	$717.31M	N/A	N/A	60	Gap Down High Trading Volume
NNNN Anbio Biotechnology	0.8968 of 5 stars	$16.47 -1.0%	N/A	N/A	$2.39B	$8.65M	N/A	27	Positive News Gap Up
BHVN Biohaven	2.9566 of 5 stars	$15.49 +14.1%	$22.27 +43.8%	+12.0%	$2.33B	N/A	N/A	239	Analyst Forecast Gap Down
KOD Kodiak Sciences	1.7721 of 5 stars	$36.63 +1.4%	$42.14 +15.1%	+871.4%	$2.26B	N/A	N/A	90	Positive News Gap Down
NTLA Intellia Therapeutics	2.7305 of 5 stars	$15.75 +0.5%	$20.46 +29.9%	+74.5%	$2.19B	$66.09M	N/A	600	Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CADL) was last updated on 6/29/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Candel Therapeutics (CADL) Competitors

CADL vs. NNNN, BHVN, KOD, NTLA, and PHVS

How does Candel Therapeutics compare to Anbio Biotechnology?

Summary

How does Candel Therapeutics compare to Biohaven?

Summary

How does Candel Therapeutics compare to Kodiak Sciences?

Summary

How does Candel Therapeutics compare to Intellia Therapeutics?

Summary

How does Candel Therapeutics compare to Pharvaris?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CADL vs. The Competition

Candel Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Candel Therapeutics (CADL) Competitors

CADL vs. NNNN, BHVN, KOD, NTLA, and PHVS

How does Candel Therapeutics compare to Anbio Biotechnology?

Is CADL or NNNN more profitable?

Does the media favor CADL or NNNN?

Do analysts recommend CADL or NNNN?

Which has better valuation & earnings, CADL or NNNN?

Which has more volatility & risk, CADL or NNNN?

Do institutionals & insiders have more ownership in CADL or NNNN?

Summary

How does Candel Therapeutics compare to Biohaven?

Which has higher earnings and valuation, CADL or BHVN?

Do institutionals and insiders hold more shares of CADL or BHVN?

Which has more risk and volatility, CADL or BHVN?

Is CADL or BHVN more profitable?

Do analysts rate CADL or BHVN?

Does the media favor CADL or BHVN?

Summary

How does Candel Therapeutics compare to Kodiak Sciences?

Do institutionals & insiders hold more shares of CADL or KOD?

Do analysts rate CADL or KOD?

Which has preferable valuation and earnings, CADL or KOD?

Which has more volatility and risk, CADL or KOD?

Is CADL or KOD more profitable?

Does the media favor CADL or KOD?

Summary

How does Candel Therapeutics compare to Intellia Therapeutics?

Which has more risk & volatility, NTLA or CADL?

Do institutionals & insiders hold more shares of NTLA or CADL?

Do analysts prefer NTLA or CADL?

Is NTLA or CADL more profitable?

Does the media refer more to NTLA or CADL?

Which has preferable valuation and earnings, NTLA or CADL?

Summary

How does Candel Therapeutics compare to Pharvaris?

Which has more volatility & risk, PHVS or CADL?

Does the media refer more to PHVS or CADL?

Is PHVS or CADL more profitable?

Which has better earnings & valuation, PHVS or CADL?

Do analysts rate PHVS or CADL?

Do institutionals and insiders hold more shares of PHVS or CADL?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CADL vs. The Competition

Candel Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools